Research progress on breast cancer surgery in St.Gallen international conference and interpretation

doi:10.3877/cma.j.issn.1674-0807.2017.04.002

Abstract

Abstract:

St. Gallen international breast cancer conference is held once every 2 years,focusing on the standard and implementation in the diagnosis and treatment of early breast cancer patients. In the conference,the world-renowned experts gathered to discuss the hot topics, develop the consensus and promote it globally.In this paper, we reported the current research progress in breast surgery reported in 2017 St. Gallen conference and make a specific interpretation.

Key words: Breast neoplasms, urgical procedures, operative, Congresses as topic

Zhimin Shao, Junjie Li. Research progress on breast cancer surgery in St.Gallen international conference and interpretation[J]. Chinese Journal of Breast Disease(Electronic Edition), 2017, 11(04): 198-202.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2017.04.002

https://zhrxbzz.cma-cmc.com.cn/EN/Y2017/V11/I04/198

References 17

[1]	Li J, Liu Y, Jiang Y, et al. Breast cancer-specific mortality pattern and its changing feature according to estrogen receptor status in two time periods[J]. PLoS One,2016,11(6):e0157322.
[2]	Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer:20 year follow-up of the EORTC 10801 phase 3 randomised trial[J]. Lancet Oncol,2012,13(4):412-419.
[3]	van Maaren MC, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a populationbased study[J]. Lancet Oncol,2016,17(8):1158-1170.
[4]	Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer [J]. J Clin Oncol, 2014,32(14):1507-1515.
[5]	Bodilsen A, Bjerre K, Offersen BV, et al. Importance of margin width in breast-conserving treatment of early breast cancer[J]. J Surg Oncol,2016,113(6):609-615.
[6]	Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ[J]. Ann Surg Oncol,2016,23(12):3801-3810.
[7]	Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18[J]. J Clin Oncol,1997,15(7):2483-2493.
[8]	Hyslop T, Alvarado M, Forero A, et al. Abstract S3-06:Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017[J]. Cancer Res, 2016, 76 (4 Suppl): Abstract S3-06.
[9]	中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015 版)[J].中国癌症杂志,2015,25(9):692-754.
[10]	Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases(IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol,2013,14(4):297-305.
[11]	邵志敏,李俊杰.2015 年St. Gallen 国际乳腺癌研讨会乳腺癌新的诊疗理念[J/CD].中华乳腺病杂志(电子版),2015,9(2):65-69.
[12]	Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance)ACOSOG Z0011 Randomized Trial[J]. Ann Surg,2016,264(3):413-420.
[13]	Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer(EORTC 10981-22023 AMAROS): a randomised, multicentre, openlabel, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014,15(12):1303-1311.
[14]	Li JW, Mo M,Yu KD,et al. ER-poor and HER2-positive:a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy[J]. PLoS One,2014,9(12):e114646.
[15]	Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy(SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol,2013,14(7):609-618.
[16]	Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study[J]. J Clin Oncol,2015,33(3):258-264.
[17]	Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node Identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)[J].Ann Surg,2015,261(3):547-552.

Please choose a citation manager

Content to export